A5045028849- Cancer-related Molecular Pathways
- Hedgehog Signaling Pathway Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Pancreatic and Hepatic Oncology Research
- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Ubiquitin and proteasome pathways
- Hepatitis B Virus Studies
- HIV Research and Treatment
Universidade Federal do Espírito Santo
2023
We report the case of a 68-year-old male with alcohol-related cirrhosis, diagnosed hepatocellular carcinoma (HCC) not eligible for liver transplant. After immunotherapy atezolizumab associated bevacizumab, he underwent successful living donor transplantation (LT), showing disease evidence or graft injury, maintaining clinically and radiologically stable 14 months after surgery. This is combined plus bevacizumab being used as bridge to LT in patient HCC, an important finding therapy patients...
SUMMARY Background Li-Fraumeni Syndrome (LFS) is a predisposition associated with early onset malignant tumors caused by germline pathogenic variants in the TP53 gene. Although rare worldwide, LFS prevalent Southern Brazil due to founder variant, c.1010G>A, p.Arg337His (R337H), discovered through its association risk of childhood adrenal cortical carcinoma. Methods Here, we have analyzed tumor patterns, cancer risk, sex differences and temporal trends cohort 303 adult R337H carriers...
Relatamos o caso de um homem 68 anos, com cirrose hepática etiologia alcoólica, diagnosticado carcinoma hepatocelular (CHC) não elegível para transplante hepático. Após imunoterapia atezolizumabe associado ao bevacizumabe, ele foi submetido a hepático (TH) doador vivo sucesso, mostrando evidencia doença ou lesão no enxerto, mantendo-se clínica e radiologicamente estável 14 meses após cirurgia. Esse é relato sucesso da combinação mais bevacizumabe sendo usados como ponte TH em paciente CHC,...